Targeted Therapy: Its Status and Promise in Selected Solid Tumors Part I
2012
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
40
References
2
Citations
NaN
KQI